All Releases
 |
Alimera Sciences' Iluvien(R) Receives FDA Priority Review for the Treatment of Diabetic Macular Edema
Aug 30, 2010
|
14.3 KB |
|
| |
ATLANTA, Aug 30, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien(R) (fluocinolone ace...
|
|
Photo Release -- Alimera Sciences Announces Key Executive Promotions
Aug 16, 2010
|
14.7 KB |
|
| |
ATLANTA, Aug 16, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the promotions of Richard S. Eiswirth, Jr. to chief operating officer, and Davi...
|
|
Alimera Sciences Reports Second Quarter 2010 Financial Results
Aug 12, 2010
|
20.3 KB |
|
| |
ATLANTA, Aug 12, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), today announced financial results for the second quarter ended June 30, 2010 and provided an update on progress toward achieving its 2010 goals.
"We are pleased that we successfully achieved our regulatory submission goals for ou...
|
|
Alimera Sciences to Hold Conference Call to Discuss Second Quarter 2010 Financial Results
Jul 29, 2010
|
10.5 KB |
|
| |
ATLANTA, Jul 29, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter 2010 financial results after the market...
|
|
Alimera Sciences Submits Iluvien(R) MAA for the Treatment of Diabetic Macular Edema
Jul 8, 2010
|
13.9 KB |
|
| |
ATLANTA, Jul 8, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare produ...
|
|
Alimera Sciences Submits Iluvien(R) NDA to the FDA for the Treatment of Diabetic Macular Edema
Jun 29, 2010
|
13.8 KB |
|
| |
ATLANTA, Jun 29, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
|
|
Alimera Sciences Reports First Quarter 2010 Financial Results
Jun 3, 2010
|
17.9 KB |
|
| |
ATLANTA, Jun 3, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), today announced financial results for the first quarter ended March 31, 2010 and provided an update on progress toward achieving its 2010 goals.
"We have made important progress recently, including announcing positive results from...
|
|
Alimera Announces Iluvien(R) Post 24-Month Visual Acuity Data Indicates Significant Long-Term Improvement in DME
May 27, 2010
|
14.7 KB |
|
| |
ATLANTA, May 27, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of data from its Phase 3 (FAME) clinical trials for Iluvien...
|
|
Alimera Sciences to Hold Conference Call to Discuss First Quarter 2010 Financial Results
May 26, 2010
|
10.5 KB |
|
| |
ATLANTA, May 26, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its first quarter 2010 financial results will be released after the market...
|
|
Alimera Sciences to Present at Citi 2010 Global Health Care Conference
May 20, 2010
|
10.8 KB |
|
| |
ATLANTA, May 20, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer, is scheduled to present ...
|
|
Alimera Sciences Prices Initial Public Offering
Apr 23, 2010
|
12.8 KB |
|
| |
ATLANTA, Apr 23, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM), ("Alimera") today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
In addition, Alimera has granted the underwriters a 30-day op...
|
|
Alimera Announces Positive Results from the Two Phase 3 Fame™ Trials of Iluvien® in Patients with Diabetic Macular Edema
Dec 23, 2009
|
15.1 KB |
|
| |
For the patients treated with the low dose of Iluvien, 26.8% to 30.6% demonstrated improvement in best corrected visual acuity (BCVA) of 15 letters from baseline, and for patients receiving the high dose of Iluvien, 26.0% to 31.2% demonstrated improvement of 15 or more letters in BCVA from baseline, both at 2 years.
Compan...
|
|
Alimera Reports Safety And Efficacy Results From The 18-Month Interim Readout Of The Human PK Iluvien® Study
Sep 29, 2009
|
11.9 KB |
|
| |
ATLANTA, September 29, 2009 -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. &n...
|
|
Alimera Sciences Begins Pilot Study Of Iluvien in Patients With Macular Edema Secondary To Retinal Vein Occlusion
Sep 23, 2009
|
10.3 KB |
|
| |
ATLANTA, September 23, 2009 -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien® in patients with macular ede...
|
|
Alimera Sciences Closes $5 Million In Extended Series C Financing
Aug 27, 2009
|
10.0 KB |
|
| |
ATLANTA, August 27, 2009—Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008. In connection with this financing, the purchasers of the $5 million in Series C preferred stock received warrants for an additional $10 million in Series C ...
|
|
Alimera Sciences Announces Presentation Of Data From The 12-Month Interim Readout Of The Human PK ILUVIEN™ Study At ARVO 2009 Annual Meeting
May 4, 2009
|
9.9 KB |
|
| |
ATLANTA, May 4, 2009 – Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien&trade...
|
|
Alimera Sciences’ Iluvien™ Phase 3 Studies For DME Pass Final DSMB Review Prior To October Readout
Apr 8, 2009
|
10.5 KB |
|
| |
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien&tr...
|
|
Alimera Reports Favorable Safety And Efficacy Results From The 12-Month Interim Readout Of The Human PK Iluvien™ Study
Mar 12, 2009
|
12.1 KB |
|
| |
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien™. Iluvien is an intravitreal inse...
|
|
Alimera Sciences Begins Pilot Study To Assess Safety and Efficacy of Iluvien™ In Patients With Bilateral Geographic Atrophy Due To AMD
Dec 11, 2008
|
10.4 KB |
|
| |
ATLANTA, December 11, 2008 -- Alimera Sciences Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien™ in patients with bilateral g...
|
|
Alimera Reports Results from the Six-Month Interim Readout of the Human PK Iluvien™ Study
Oct 1, 2008
|
|
| |
ATLANTA, October 1, 2008 -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien™.
...
|
|
|
Shareholder Briefcase
Printed Materials
Download Library
Snapshot
RSS News Feeds